Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights

Opinion
Video

Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.

Video content above is prompted by the following:

  • Briefly outline the evolving role of PSMA PET imaging in assessing for posttreatment response and how you incorporate it in your practice.
  • What is your timing protocol for postradiation PSMA PET imaging?
  • Do you routinely use PSMA PET for posttreatment response assessment?
  • What value may PSMA-PET posttreatment imaging offer compared with PSA monitoring alone?
  • What do available data demonstrate, and how do these findings inform your decisions in this setting?
    • 18F PSMA-1007 PET/CT vs PSA (Kleiburg et al. Eur J Rad. 2024)
    • 68GaPSMA-11 (Esen et al. J Clin Oncol. 2023.)
    • 68Ga-PSMA or 18F-DCFPyL-PSMA (Sutera et al. Adv Rad Onc. 2024) 
Recent Videos
2 experts in this video
2 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
2 experts are featured in this series.
Related Content
Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Ariana Pelosci
April 17th 2025
Article

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

PROSTOX ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore
April 9th 2025
Article

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Tim Cortese
March 26th 2025
Article

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

NeuroSAFE Improves Erectile Function, Urinary Continence in Prostate Cancer

Roman Fabbricatore
March 24th 2025
Article

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.